Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Enovis Corp (ENOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: ENOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $56.5
1 Year Target Price $56.5
| 7 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.7% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.89B USD | Price to earnings Ratio - | 1Y Target Price 56.5 |
Price to earnings Ratio - | 1Y Target Price 56.5 | ||
Volume (30-day avg) 11 | Beta 1.83 | 52 Weeks Range 28.83 - 49.83 | Updated Date 07/2/2025 |
52 Weeks Range 28.83 - 49.83 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -37.65% | Operating Margin (TTM) 0.9% |
Management Effectiveness
Return on Assets (TTM) 0.92% | Return on Equity (TTM) -27.35% |
Valuation
Trailing PE - | Forward PE 10.76 | Enterprise Value 3306611144 | Price to Sales(TTM) 0.88 |
Enterprise Value 3306611144 | Price to Sales(TTM) 0.88 | ||
Enterprise Value to Revenue 1.54 | Enterprise Value to EBITDA 22.42 | Shares Outstanding 57123100 | Shares Floating 56402729 |
Shares Outstanding 57123100 | Shares Floating 56402729 | ||
Percent Insiders 1.54 | Percent Institutions 117.9 |
Analyst Ratings
Rating 3 | Target Price 56.5 | Buy 3 | Strong Buy 7 |
Buy 3 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Enovis Corp
Company Overview
History and Background
Enovis Corp, formerly DJO Global, has a long history in orthopedic and medical technology. Founded in 1982, the company has grown through acquisitions and organic growth to become a leading player in its industry.
Core Business Areas
- Reconstructive: Hip, knee and shoulder joint reconstruction devices. Provides products and solutions for large joint reconstruction and bone preserving procedures.
- Prevention and Recovery: Non-surgical bracing and rehabilitation equipment, including orthopedic bracing, vascular therapy, and pain management solutions. Focuses on products that support injury prevention and post-operative recovery.
Leadership and Structure
Matt Trerotola serves as the CEO. The company has a traditional corporate structure with various functional departments, including R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- DJO Bracing and Supports: Orthopedic braces for various body parts, used for injury prevention and rehabilitation. Competitors include Bauerfeind, Ossur, and Breg. Market share data for specific product lines is proprietary.
- DJO Surgical: Joint reconstruction implants, including hip, knee, and shoulder implants. Competitors include Stryker, Zimmer Biomet, and Johnson & Johnson (DePuy Synthes). Specific market share data is proprietary.
- DJO Exos: Customizable and waterproof bracing solution. Competitors include conventional casts and splints. Specific market share data is proprietary.
Market Dynamics
Industry Overview
The orthopedic and rehabilitation industry is driven by aging populations, increasing sports-related injuries, and technological advancements in implant materials and surgical techniques. There's a growing demand for minimally invasive procedures and personalized medicine.
Positioning
Enovis Corp holds a strong position in the market, with a focus on innovation and a broad product portfolio. Its competitive advantage lies in its established brand reputation and global distribution network.
Total Addressable Market (TAM)
The global orthopedic device market is expected to reach hundreds of billions of dollars. Enovis is well-positioned to capture a significant portion of this TAM, focusing on segments within reconstructive and preventative/recovery care.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Strong brand recognition
- Global distribution network
- Focus on innovation
Weaknesses
- Dependence on acquisitions for growth
- Integration challenges after acquisitions
- Exposure to regulatory changes
- Pricing pressure from competitors
Opportunities
- Expanding into emerging markets
- Developing new minimally invasive technologies
- Leveraging data analytics for personalized medicine
- Partnerships with hospitals and clinics
Threats
- Increased competition from established players and new entrants
- Product liability lawsuits
- Economic downturns affecting healthcare spending
- Reimbursement pressures from insurance companies
Competitors and Market Share
Key Competitors
- ZBH
- BSX
- JNJ
Competitive Landscape
Enovis faces competition from larger, more established players in the orthopedic device market. Its competitive advantage lies in its specialized products and strong customer relationships.
Major Acquisitions
acquired company name
- Year: 2023
- Acquisition Price (USD millions): 125
- Strategic Rationale: Expanded product portfolio and market presence in the regenerative medicine sector.
Growth Trajectory and Initiatives
Historical Growth: Enovis's historical growth has been driven by a combination of organic growth and strategic acquisitions.
Future Projections: Analyst projections suggest continued growth for Enovis, driven by its innovative product portfolio and expansion into new markets.
Recent Initiatives: Recent initiatives include investments in R&D, new product launches, and expansion of its global distribution network.
Summary
Enovis Corp demonstrates a solid market presence with its diversified product offerings. Its growth strategy, incorporating acquisitions, expands its reach. Strong market dynamics and internal strengths support further growth. Vigilance against competition and economic factors are critical for sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enovis Corp
Exchange NYSE | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2008-05-08 | CEO & Director Mr. Damien McDonald | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7367 | Website https://www.enovis.com |
Full time employees 7367 | Website https://www.enovis.com | ||
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company's Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.